Michael Bradshaw, MD
Psychiatry · Jacksonville, NCNPI 1104311539
Payments from drug & device makers
Across 674 payments — averaging $14.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$917
- Teva Pharmaceuticals USA, Inc.$846
- Alkermes, Inc.$739
- plus $4K from 16 others
What the payments were for
- Food & beverage$9,69498%
- Education$1782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 88 | $1,528 |
| Otsuka America Pharmaceutical, Inc. | 79 | $1,206 |
| Vanda Pharmaceuticals Inc. | 69 | $1,119 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $917 |
| Teva Pharmaceuticals USA, Inc. | 99 | $846 |
| Alkermes, Inc. | 59 | $739 |
| Johnson & Johnson(2 entities) | 34 | $715 |
| Axsome Therapeutics, Inc. | 33 | $531 |
| E.r. Squibb & Sons, L.L.C. | 25 | $448 |
| Corium, LLC | 43 | $419 |
| Lundbeck LLC | 13 | $252 |
| Supernus Pharmaceuticals, Inc. | 22 | $219 |
| Merck | 11 | $214 |
| Tris Pharma Inc | 13 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $124 |
| Almatica Pharma LLC | 7 | $113 |
| Neurocrine Biosciences, Inc. | 5 | $93 |
| Ironshore Pharmaceuticals Inc. | 4 | $65 |
| Collegium Pharmaceutical, Inc. | 3 | $59 |
| Neos Therapeutics, LP | 3 | $47 |
| Lilly USA, LLC | 2 | $29 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
How this compares
$9,872 in reported general payments places this provider in the 90th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 69 | $102,474 |
| Invega SustennaPaliperidone Palmitate | 25 | $101,707 |
| RexultiBrexpiprazole | 42 | $86,425 |
| Abilify MaintenaAripiprazole | 21 | $58,849 |
| LybalviOlanzapine/Samidorphan Malate | 20 | $36,442 |
| Lurasidone Hcl | 78 | $22,944 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $15,807 |
| Aripiprazole | 211 | $13,985 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $11,932 |
| TrintellixVortioxetine Hydrobromide | 12 | $7,408 |
| BelsomraSuvorexant | 16 | $7,095 |
| Divalproex Sodium ErDivalproex Sodium | 99 | $7,003 |
| Atomoxetine Hcl | 38 | $5,712 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 41 | $5,068 |
| QelbreeViloxazine Hcl | 11 | $3,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,206 | $145,27463 claims |
| AbbVieVraylar | $1,528 | $102,47469 claims |
| Johnson & JohnsonInvega Sustenna | $715 | $101,70725 claims |
| Alkermes, Inc.Lybalvi | $739 | $36,44220 claims |
| Axsome Therapeutics, Inc.Auvelity | $531 | $11,93212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $124 | $7,40812 claims |
| MerckBelsomra | $214 | $7,09516 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $219 | $3,96011 claims |
| Almatica Pharma LLCSertraline Hcl | $113 | $737176 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Jacksonville
- Antonio CusiJacksonville$147K
- Ajay VeeragandhamJacksonville$21K
- Craig ChepkeHuntersville$4.1M
- James BarkerHickory$4.1M
- Mark ReynoldsDurham$3.2M
- Oleg TcheremissineCharlotte$2M
- Richard WeislerRaleigh$1.2M
- Dan BlazerDurham$1M
- Samantha Meltzer-BrodyChapel Hill$909K
- Andrew KrystalDurham$754K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.